logo
Plus   Neg
Share
Email

AIG Swings To Profit In Q4, Beats Estimates

American International Group, Inc. (AIG) Thursday reported a swing to fourth quarter net profit attributable to AIG common shareholders of $922 million, or $1.03 per share, compared to net loss attributable to AIG common shareholders of $622 million, or $0.70 per share, in the prior-year quarter.

The company said the favorable impact of General Insurance underwriting and
reinsurance actions, favorable net prior year loss reserve development of $153
million, a reduction in pre-tax net catastrophe losses of $385 million compared to the prior-year
quarter, and an increase of $833 million in net investment income helped to record the black from the red.

On an adjusted basis, earnings were $919 million, or $1.03 per share. On average, Analysts polled by Thomson Reuters expected the company to earn $1.00 per share.

For the full year of 2019, net profit attributable to AIG common
shareholders was $3.3 billion, or $3.74 per share, compared to a
net loss attributable of $6 million, or $0.01 per share, in the prior year. Adjusted after-tax income
attributable to AIG common shareholders was $4.1 billion, or $4.59 per
common share, for the full year of 2019.

AIG said it remains committed to achieving a 10 percent Adjusted ROCE
by the end of 2021.

In a separate announcement, AIG's Directors declared a quarterly
cash dividend of $0.32 per share on common stock, par value $2.50 per
share. The dividend will be payable on March 30, 2020 to stockholders on record at
the close of business on March 16, 2020.

The Board also declared a quarterly cash dividend of $365.625 per share on
AIG Series A 5.85 percent Non-Cumulative Perpetual Preferred Stock, with a liquidation
preference of $25,000 per share, holders of depositary shares will receive $0.365625 per depositary
share. The dividend is payable on March 16, 2020 to holders of record at the
close of business on February 28, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Novacyt S.A. said it is seeing unprecedented demand for the novel coronavirus or COVID-19 diagnostic test kit developed by Primerdesign, the company's molecular diagnostics division based in the UK. As of March 27, Primerdesign has sold and received orders for more than 17.8 million pounds of its CE-Mark COVID-19 tests. Novacyt is currently selling its COVID-19 test to more than 80 countries. The U.S. Food and Drug Administration has issued an Emergency Use Authorization to allow anti-malaria drugs hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile as possible treatments for coronavirus (COVID-19) patients. This is the first EUA for a drug related to the COVID-19 response. Gilead Sciences Inc. said it is transitioning to "expanded access programs" from "compassionate use" programs for its experimental anti-coronavirus drug, remdesivir. The company noted that the expanded access will allow hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at one time, as they struggle to deal with the COVID-19 or coronavirus pandemic.
Follow RTT
>